CompletedNot Applicable

DERM NMSC Validation Study

United Kingdom572 participantsStarted 2020-06-26

Plain-language summary

This study aims to establish the effectiveness of an Artificial Intelligence (AI) algorithm (DERM) to determine the presence of Basal Cell Carcinoma (BCC) and Squamous Cell Carcinoma (SCC) and frequently observed benign conditions, when used to analyse images of skin lesions taken by commonly available smart phone cameras.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study, * Male or Female, aged 18 years or above, * Have at least suspicious skin lesion which is suitable for photographing (\<15mm, not located on an anatomical site inappropriate to photograph (genitalia, hair-bearing areas, under nails), not previously biopsied, not located in an area of visible scarring or tattooing), * In the Investigator's opinion, able and willing to comply with all study requirements. Exclusion Criteria: * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study

What they're measuring

AUROC of DERM performance when analysing images of biopsied lesions

Timeframe: Study completion

Trial details

NCT IDNCT04116983

SponsorSkin Analytics Limited

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2022-02-28

View on ClinicalTrials.gov More Non-melanoma Skin Cancer trials